Clinical Trial Update: Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 trial update on bevacizumab plus chemotherapy for EGFR-TKI–resistant non-squamous non-small cell lung cancer, focusing on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lung, Carcinoma | Phase 2 | Status: UNKNOWN